Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.

Takeda Pharmaceuticals: Global Homepage

# FY2024 Q2 Financial Results

*	***Revenue Growth of +13.4% at Actual Exchange Rates (AER); +5.0% at Constant Exchange Rate (CER) Driven by Continued Advancement of Growth & Launch Products (+18.7% at CER)***
*	***Core Operating Profit Increase of +12.9% at CER; Core Operating Profit Margin of 30.2%***
*	***Double-Digit Revenue Growth of ENTYVIO® at CER Driven by Launch of ENTYVIO® Pen in the U.S***. 
*	***Geographical Expansion with Approvals of ADZYNMA® in EU and FRUZAQLA® in Japan ***
*	***Late-Stage Pipeline Advances with the Start of Phase 3 Trial of TAK-861 in Narcolepsy Type 1***
*	***Company will Hold R&D Day for Investors and Media on December 12 (Eastern) / 13 (Japan) ***


**OSAKA, Japan, October 31, 2024** – Takeda ([TSE:4502/NYSE:TAK](https://www.takeda.com/investors/stock-information/)) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full year forecasts and Management Guidance to reflect stronger than anticipated first-half performance (including milder than anticipated generic erosion of VYVANSE® in the U.S.) and revised foreign exchange assumptions.

The strong performance of Takeda’s Growth and Launch Product portfolio, which grew 18.7% at CER and represented 47% of total revenue, reinforces the company’s confidence in returning to sustainable revenue and profit growth. 

The initiation of TAK-861’s Phase 3 trial in August for narcolepsy type 1 demonstrates Takeda’s strength in advancing its promising late-stage pipeline to develop life-transforming treatments. More details on the company’s R&D strategy and pipeline updates, including commercial prospects, will be presented at Takeda’s R&D Day taking place on December 12 (EST) / 13 (JST), 2024.  

**Takeda chief executive officer, Christophe Weber, commented:**

“In the first half of fiscal year 2024, we made further progress in advancing our pipeline, including the initiation of our TAK-861 Phase 3 trial for narcolepsy type 1. Our late-stage programs continue to advance, with several in Phase 3 development this fiscal year, and have the potential to transform the lives of patients around the world.

“Our commercial execution has positioned us for sustainable growth despite a dynamic and competitive environment. Bolstered by the continued strong performance of our Growth & Launch Products, including a return to double-digit growth of ENTYVIO®, lifecycle management approvals and successful launches of new products such as FRUZAQLA® in our oncology portfolio, our business and long-term outlook remains strong.”

**Takeda chief financial officer, Milano Furuta, commented:**

“We are upgrading our FY2024 full year outlook, reflecting stronger than anticipated first half performance as well as updated foreign exchange assumptions for the year. Full year guidance reflects our intention to increase R&D investment in the second half to support our late-stage pipeline. 

“We remain confident in delivering sustainable growth with our Growth & Launch Products and promising late-stage pipeline. Implementation of our multi-year program to improve our efficiency through organizational agility, procurement savings and data, digital and technology is progressing as planned. We continue to drive these initiatives to improve our Core Operating Profit Margin from FY2025 towards our low-to-mid 30s% target.”

Takeda announced strong earnings results for the first half of fiscal year 2024, with continued momentum in its Growth & Launch Products and advancements in its promising late-stage pipeline.

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

**OSAKA, Japan, October 31, 2024** – Takeda ([TSE:4502/NYSE:TAK](/investors/overview/)) today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2025 (FY2024), as below.

1. Revised Forecast for Full Year Consolidated Financials for the Fiscal Year Ending March 31, 2025

OSAKA, Japan, October 31, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2025 (FY2024), as below.

Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS)

**OSAKA, Japan, and CAMBRIDGE, Massachusetts, October 17, 2024** – Takeda ([TSE:4502/NYSE:TAK](https://www.takeda.com/investors/)) today announced that it will host its earnings call on Thursday, October 31, 2024, to present its 1st half results for fiscal year 2024. Details below:

**Date/Time**: Thursday, October 31, 19:00-20:15 (JST) / 10:00-11:15 (GMT) / 06:00-07:15 (EDT)

**Participants (planned):**

* Christophe Weber, President and Chief Executive Officer
* Milano Furuta, Chief Financial Officer
* Andy Plump, President, Research & Development
* Other executive leadership

**Content:** Presentation, Q&A session - presented in English and Japanese with simultaneous interpretation.

**Webinar platform and registration**: The call will be held using the Zoom platform and Zoom simultaneous interpretation function. Kindly pre-register from the below link:

[https://zoom.us/webinar/register/WN_PwdLT0NuTrWeZn-HsRIcaw](https://zoom.us/webinar/register/WN_PwdLT0NuTrWeZn-HsRIcaw)

If you wish to ask questions during the Q&A session, please join from the above link.

**Presentation material:** Presentation material will become available on [Takeda’s website](https://www.takeda.com/investors/financial-results/quarterly-results/) at 15:00 (JST) / 6:00 (GMT) / 2:00 (EDT) on Thursday, October 31st.

**On-demand Replay:** An on-demand replay will be made available on [Takeda’s website](https://www.takeda.com/investors/financial-results/quarterly-results/) after the conclusion of the event.

**Notes:** For optimal performance of simultaneous interpretation and raise-hand functions, please upgrade your Zoom application to the latest version [here](https://zoom.us/support/download).

## About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit [www.takeda.com](http://www.takeda.com/).

### Media Contacts:

U.S., Japanese and International Media

Brendan Jennings

[brendan.jennings@takeda.com](mailto:brendan.jennings@takeda.com)


## Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

## Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: [https://www.takeda.com/investors/sec-filings-and-security-reports/](https://www.takeda.com/investors/sec-filings-and-security-reports/)or at [www.sec.gov](http://www.sec.gov/). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.












Takeda today announced that it will host its earnings call on Thursday, October 31, 2024, to present its 1st half financial results for fiscal year 2024.

 Takeda to Hold Earnings Call for Fiscal Year 2024 1st Half on October 31

Takeda announces Japanese Ministry of Health approval for FRUZAQLA (fruquintinib) to treat unresectable advanced or recurrent colorectal cancer, based on positive Phase 3 FRESCO-2 trial results.

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

<h2 style="text-align: center;">Recent News</h2>



We exist to create better health for people and a brighter future for the world. While the science and technology we advance are constantly evolving, our ambition remains. We move science forward, so we can transform more lives.

Work with globally diverse colleagues who are committed to bringing Better Health to people and a Brighter Future to the world.


### Join Us



/careers

Discover our balanced, diverse portfolio and strategy for sustainable, patient-centered and resilient growth.


### Investors



/investors/overview

Fueled by our inherent curiosity, we translate science into highly innovative, life-transforming medicines.


### R\&D



/science/research-and-development

## Better Health, Brighter Future



Understanding and addressing life-limiting gastrointestinal and inflammatory diseases

Working to transform treatments in immunology, hematology, metabolic and lysosomal storage disorders

Improving the lives of patients with rare and complex chronic diseases through innovation in plasma

Aspiring to cure cancer, with inspiration from patients and innovation from everywhere

Driving medical innovation for patients with neurological diseases

Addressing unmet global health needs through vaccine development against infectious diseases

## Our Areas of Focus


Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

## Sign up for investors newsletter



Home

Cancel

Links to sites outside of takeda.com are provided as a resource to the audiences. Please note that Takeda is not responsible or liable for any third-party website and the website may not be appropriate for all audiences. 

To stay on the current website, select “Cancel”


FY2024 Q2 Financial Results

Recent News

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS)

Takeda to Hold Earnings Call for Fiscal Year 2024 1st Half on October 31

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Better Health, Brighter Future

Join Us

Investors

R&D

Our Areas of Focus

Gastrointestinal and Inflammation

Rare Diseases

Plasma-Derived Therapies

Oncology

Neuroscience

Vaccines

Sign up for investors newsletter